Tirzepatide 60mg
Dual GIP / GLP-1 receptor agonist
≥99.0%
Third-Party
COA
Also available in 10mg · 15mg · 30mg · 45mg — compare all sizes
Complete your research kit
Also searched as: Tirz, GIP/GLP-1 dual agonist
Third-Party Tested
HPLC & mass spec verified purity
Batch Specific COA
Certificate with every batch
Discreet Packaging
Plain, unbranded, tamper-evident
Same-Day Dispatch
Before 2PM AEST, Australia-wide
Tirzepatide 60mg is a research compound supplied for laboratory investigation of incretin-receptor signalling and related metabolic pathways. Tirzepatide is a synthetic peptide with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This 60mg presentation provides researchers with a higher-quantity format for controlled experimental work. Tirzepatide 60mg products should be handled exclusively as laboratory research materials and not as medicines or products for personal use.
What Is Tirzepatide 60mg?
Tirzepatide is a single synthetic peptide engineered to interact with two established incretin receptors: GIPR and GLP-1R. These receptors participate in signalling networks associated with glucose regulation, insulin secretion, energy balance and broader metabolic processes.
The dual-receptor profile distinguishes tirzepatide from compounds designed primarily around GLP-1 receptor activity alone. Researchers have therefore examined tirzepatide as a tool for understanding how simultaneous activation of GIP and GLP-1 pathways influences metabolic signalling.
The 60mg designation refers to the nominal quantity supplied per product presentation and does not indicate a human dose or administration recommendation.
Key Research Areas
Tirzepatide research has focused on several interconnected areas, including:
Findings should always be interpreted according to the experimental model and study design rather than assumed to represent universal biological outcomes.
Why Researchers Study Tirzepatide 60mg
A major point of scientific interest is tirzepatide’s ability to engage two incretin-receptor systems within one molecular structure. GIPR and GLP-1R have overlapping but distinct physiological signalling functions.
This makes tirzepatide useful for investigating questions concerning receptor co-activation, downstream signalling and interactions between incretin pathways. The 60mg format may also suit laboratory projects requiring a larger nominal quantity of the same research compound.
Key Research Areas at a Glance
Tirzepatide 60mg in Australia
Researchers looking for Tirzepatide 60mg Australia should check the supplier’s current product listing for stock status, price, domestic shipping information and batch documentation before ordering.
When comparing Tirzepatide 60mg online, analytical transparency should be considered alongside nominal vial quantity. Where provided, batch-specific CoA documentation allows researchers to assess analytical information associated with the material received.
Specifications
Certificate of Analysis
Quality, Purity and Batch Testing
Researchers should evaluate Tirzepatide 60mg using the analytical documentation supplied with the relevant batch. Where available, a batch-specific Certificate of Analysis (CoA) can provide information concerning identity, purity and analytical findings.
Methods such as HPLC may be used to assess chromatographic purity, while LC-MS can support molecular identity verification. Analytical purity should not be interpreted as evidence of clinical safety or therapeutic effectiveness.
Storage & Handling
Storage and Laboratory Handling
- Lyophilised storage: Follow the storage conditions stated on the product label and applicable batch documentation.
- After reconstitution: Where validated post-reconstitution stability information is not supplied, researchers should follow their established laboratory protocol and batch documentation rather than assuming a specific stability period.
Reconstitution calculator: Tirzepatide 60mg
Work out concentration and the volume to draw for each aliquot before you add diluent.
- Concentration
- –
- Volume per aliquot
- –
- On a 1 mL (U-100) syringe
- –
- Aliquots per vial
- –
A laboratory arithmetic aid only. Verify every calculation independently. Not dosing guidance; research use only.
Tirzepatide 60mg: Frequently Asked Questions
It is a synthetic dual GIP/GLP-1 receptor agonist supplied in a 60mg nominal research format.
It activates GIP and GLP-1 receptors, allowing investigation of interconnected incretin and metabolic signalling pathways.
Because the molecule exhibits activity at both GIPR and GLP-1R rather than targeting only one incretin receptor.
Research includes incretin signalling, glucose regulation, metabolic pathways, energy balance and receptor biology.
Researchers should consult the specific product's analytical report for verified purity and testing information.
Where supplied, a batch-specific CoA documents analytical findings associated with the relevant production batch.
Follow the verified storage requirements shown on the product label and batch documentation.
Check the relevant Australian research supplier for current availability, pricing, analytical documentation and domestic shipping details.
No. This product is supplied strictly for in-vitro laboratory research. It is not approved for human or veterinary use and must not be consumed or administered.
Orders placed before 2PM AEST on business days are dispatched the same day from Melbourne. Standard Post takes 3–7 business days and Express Post 1–3 business days, both tracked and discreet.
Purchase Other Quantities
Tirzepatide is also available in other vial sizes. Compare the current formats below and jump straight to the quantity that fits your protocol.
Reviews
There are no reviews yet.